Sanctuary Advisors’s Janux Therapeutics JANX Stock Holding History

Sanctuary Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,926	Closed	-$243K	–	2495
2025 Q3	$243K	Buy	+9,926	New	+$242K	﹤0.01%	2140

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sanctuary Advisors's JANX Position: Q4 2025 in Review

Sanctuary Advisors sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 9,926 shares — an estimated $243K sold.

Sanctuary Advisors first reported a position in JANX in Q3 2025 and held it in 1 quarter. The position peaked at $243K in Q3 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

Sanctuary Advisors reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
Sanctuary Advisors sold 9,926 Janux Therapeutics shares in Q4 2025, an estimated $243K.
Sanctuary Advisors first reported a position in Janux Therapeutics in Q3 2025 and held it in 1 quarter.
Sanctuary Advisors's Janux Therapeutics position peaked at $243K in Q3 2025.
176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Sanctuary Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.